Piper Jaffray maintained its Athenahealth ATHN Overweight rating and $49 price target in a research report published today.
In the report, Piper Jaffray states, "Athenahealth reported nice upside on Q4 results, with EPS of $0.28 vs. consensus of $0.20, and PJC estimate of $0.21. Revenue of $64 million was $1 million ahead of our estimate. 624 doc adds in the quarter was the only blemish in the quarter. We believe the solid quarter demonstrates the leverage inherent to the model, and continue to like the stock in front of the HIMSS conference next week."
Shares of Athenahealth were at $47.50 in pre-market trading at the time of posting, down 0.36% from Thursday's market close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in